drugset / Trial / NCT00036218

Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.

NCT00036218

Phase 3 Completed 600 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary purpose of this study is to determine whether sumanirole is effective and safe in the treatment of the signs and symptoms of early Parkinson's disease.

Timeline

Start
2001-12
Primary completion
Completion
2003-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Ropinirole Small molecule
Subject sumanirole Small molecule

Indications